D,L-PDMP 80938-69-8

H1719

D,L-苏阿糖型-1-苯基-2-鱼腥草氨基酸-3-吗啉-1-丙醇盐酸 D,L-PDMP

80938-69-8

synthetic

C₂₃H₃₈N₂O₃•HCl

427

100mg

solid

98+% TLC

D,L-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol•HCl;Activity: glucosylceramide synthase inhibitor

ethanol, methanol, chloroform, DMSO

-20°C

上海惠诚生物提供D,L-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol•HCl,D,L-threo-PDMP is a glucosylceramide synthase inhibitor, an enzyme that is essential for the synthesis of a very large number of different glycolipids that are found in many organisms.1 PDMP has four possible isomers due to its two chiral centers (Dthreo, L-threo, D-erythro, and L-erythro). This product (D,L-threo-PDMP) is a mixture of D-threo (1R,2R) and L-threo (1S,2S). The D-threo isomer has been shown to be the active glucosyl ceramide synthetase inhibitor.2 However, treatment with the L-threo isomer has been shown to contribute to an increase in the amount of lactosyl ceramide and may have other effects as well.3 Due to PDMP’s ability to inhibit the joining of ceramides with carbohydrates there can be an accumulation of ceramide in the cells and this can lead to apoptosis. This process has been suggested as a treatment for cancer.4 In addition to its stereochemistry, the acyl chain of PDMP has a very marked effect on the intensity of the inhibitory action of the molecule. Conduritol beta epoxide (CBE), an inhibitor of beta-glucosidase, and l-phenyl-2-decanoylamino-3-morpholino-lpropanol (PDMP), an inhibitor of glucosylceramide synthase, can be used to create a model of Gaucher disease and consequently an accumulation of glucopsychosine.5
1. R. Vunnam, N. Radin, Chem. Phys. Lipids, Vol. 26(3) pp. 265-278, 1980
2. N. Radin et al., Journal of Cellular Physiology, Vol. 141(3) pp. 573-583, 1989
3. J. Inokuchi, S. Usuki and M. Jimbo, J. Biochem., Vol. 117(4) pp. 766-773, 1995
4. N. Radin, et al., Journal of Lipid Research, Vol. 36 pp. 611-621, 1995